These same medications are a frontline tool for managing type 2 diabetes, and about half of the patients Kami treats with GLP-1 are using it to regulate blood sugar rather than primarily to lose weight
However, this will need to be considered in the context of data from cardiovascular and kidney outcome trials involving tirzepatide
There are two hormones that make you hungry or full
Thus, establishing the enzymatic binding reaction of GSH will provide guidance for evaluating the safety and efficacy of compounds in vivo
Legitimate Research Directions: Some peptides DO have potential and are being properly studied: Thymosin Alpha-1: Immune support (approved in 35+ countries, trials in US) BPC-157: IF proper human trials ever happen LL-37: Antimicrobial applications Others: Many peptides have theoretical promise But ONLY if studied properly: Randomized controlled trials Safety studies FDA approval process Medical supervision The Problem: Most "wellness peptides" will NEVER go through this process because: They can't be patented (no profit incentive) Companies would rather sell in gray market Proper trials cost $100M+ If trials show they DON'T work, the market disappears So we're stuck in limbo: promising animal data, zero human data, aggressive marketing
A genome-wide association study identifies novel association between genetic variants in GGT7 and LINC00944 and hypertension